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micro- and biofabrication as well as 
emerging biological and computational 
tools.[1] In regenerative medicine, this 
approach requires integration of complex 
biological systems with synthetic polymer 
materials to achieve appropriate physical, 
mechanical, and biological properties.[2,3] 
Recent advancements in additive manu-
facturing techniques have resulted in 
increased functionality and complexity 
of engineered tissue structures.[4] How-
ever, broader breakthroughs have been 
hampered by technological tradeoffs 
posed by a limited understanding of the 
structural complexity of biological tis-
sues. To be able to mimic native tissue, 
the complex interplay between cells of 
different phenotypes, their local micro-
environment and their time-dependent 
interactions need to be defined.[1] Beside 
a clear set of biospecifications, individual anatomical archi-
tectures are key elements required for mimicking natural 
tissue. In this context, medical imaging enables visualization 
of the anatomical structure, leading to information-guided 
engineering of 3D models in computer-aided design (CAD) 
of the target tissue.[5] With the help of advanced computer-
aided manufacturing (CAM) techniques, polymer scaffolds 
with high resolution can be produced to support stability 
and flow transport as part of the extracellular microenviron-
ment. Considering the often orthogonal sets of material 
requirements ranging from mechanical properties to bio-
degradability, the choice of materials remains an important 
consideration during the design process.[6,7] Additionally, a 
cell-instructive protein matrix, which resembles the native 
extracellular matrix (ECM) as closely as possible in guiding 
cell attachment, orientation, proliferation and differentiation, 
is required.[8] Herein, we will focus on the various steps and 
challenges from computer-assisted manufacturing of scaffolds 
to cell seeding techniques with the goal to produce functional 
tissues (Figure 1).
2. Hallmarks of a Functional Tissue
In designing complex biological systems, engineers must 
consider the most basic properties of tissues that enable 
function. Classical tissue engineering relies on mimicking 
the extracellular matrix through the use of natural or syn-
thetic materials, typically referred to as “scaffolds” that sup-
port cells.[9] Scaffold composition, architecture, mechanical 
Synthetic biological systems are used for a myriad of applications, including 
tissue engineered constructs for in vivo use and microengineered devices 
for in vitro testing. Recent advances in engineering complex biological 
systems have been fueled by opportunities arising from the combination of 
bioinspired materials with biological and computational tools. Driven by the 
availability of large datasets in the “omics” era of biology, the design of the 
next generation of tissue equivalents will have to integrate information from 
single-cell behavior to whole organ architecture. Herein, recent trends in 
combining multiscale processes to enable the design of the next generation 
of biomaterials are discussed. Any successful microprocessing pipeline must 
be able to integrate hierarchical sets of information to capture key aspects 
of functional tissue equivalents. Micro- and biofabrication techniques that 
facilitate hierarchical control as well as emerging polymer candidates used in 
these technologies are also reviewed.
Tissue Engineering
1. Introduction
A new frontier in engineering complex biological systems 
is fueled by opportunities arising from recent advances in 
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properties, and biologically active additives should be pre-
cisely designed for the target tissue or question of interest[10] 
(Figure 2). In considering this vast design space, it should be 
appreciated that native matrix molecules assemble hierarchi-
cally to form complex and diverse suprastructures that enable 
diverse functionality ranging from the transmission of light in 
the cornea to the sustained contraction of cardiac muscle over 
entire lifetimes.[11] Nature’s capacity for precise hierarchical 
organization enables vast functionality that tissue engineers 
and materials scientists struggle to compete with. In this 
section, we briefly focus on defining aspects of the material–
biological interface that are critical to designing structures that 
retain biological relevance (Table 1).
2.1. Structure and Organization
2.1.1. Organizational Hierarchy
From the assembly of amino acids into proteins to the arrange-
ment of single cells into complex organisms, life is distinct 
in its remarkable ability to achieve complexity from simpler 
building blocks. During human embryogenesis, for example, 
the single-celled zygote undergoes many rounds of mitosis 
to transition from the single-layered blastula to a trilayered 
gastrula composed of the ectoderm, mesoderm, and endo-
derm.[10,12] From these three germ layers, sheets of connected 
cells (epithelium) or individual meshes of cells (mesenchyme) 
give rise to the four types of tissue (connective, epithelial, mus-
cular, and nervous) that constitute all organs. Complex tissues 
are arranged in a hierarchical fashion that enables specific 
function. Skeletal muscle, for instance, is a tissue composed of 
muscle cells that fuse to form myofibers composed of sarcom-
eres made of actin and myosin filaments that facilitate muscle 
contraction. Such hierarchical organization is evident across all 
tissue types and allows for the diversity of functions found in 
the human body.[13]
The major participants that are critical to tissue struc-
ture and function are: i) cells, ii) the extracellular matrix, and 
iii) signaling molecules.[14] These components work in concert 
to achieve a targeted function. Establishing the precise bal-
ance of these critical elements to either recapitulate tissue or 
facilitate its repair is the goal of tissue engineering.[15] While 
nature drives these processes through self-assembly, most 
engineers use guided or direct assembly to achieve spatial 
control over these critical elements. Strategies for harnessing 
multiscale control over biological systems have recently been 
reviewed.[13,16] Here, we limit the discussion to key findings of 
the physical and chemical aspects of the microenvironment.
2.1.2. Physical Properties
Increased attention has been given to the role of substrate 
physical properties, such as roughness, topography, and 
mechanical properties (e.g., stiffness and elasticity), in gov-
erning cell behavior.[17] Control of these physical proper-
ties is recognized as an essential prerequisite for successful 
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Table 1. Key elements of functional tissues.
Key elements of functional tissues
• Structure
Provide hierarchical organization, lend particular physical and chemical 
properties to guide proper cell behavior.
• Function
Promote regular cell phenotype specific to the tissue of interest, and 
facilitate transport of nutrients, waste, and information.
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tissue-engineered constructs.[7,14,18] Though cells are 
micrometer-sized, they contain sensory machinery that are 
below 100 nm. Underlying substrate architecture with fea-
tures below 50 nm has enabled specific cell patterning.[19] 
Topographical features at the nanometer scale can influ-
ence cell orientation and motility.[20,21] Contact guidance, a 
phenomenon whereby a cell’s interaction with its external 
environment influences its morphology and movement, is 
typically governed by micro meter (1–50 µm) and nanom-
eter (<1 µm) architectures.[22,23] Again, nanotopography can 
mediate the substrate features with which cells interact.[24] 
For example, surface roughness can alter wettability and 
affect protein binding and exchange at the surface.[25] Addi-
tionally, the geometric packing configurations of adsorbed 
proteins is affected by surface nanotopography.[26]
2.1.3. Extracellular Matrix Composition
The ECM is a complex milieu of biomacromolecules that plays 
both a structural and functional role in supporting cell mor-
phology and behavior.[27,28] ECM composition varies signifi-
cantly depending on the tissue type and disease state, but is 
generally composed of water, proteins, polysaccharides, proteo-
glycans, and a host of ECM regulators and secreted factors.[27] 
A large-scale survey of the ECM atlas found 1027 genes asso-
ciated with the human matrisome.[29] Still, elucidating the 
exact distributions and roles of each extracellular component 
remains elusive for many tissue types. Given the expansive 
and complex roles and interactions of these components, 
recent efforts have aimed at organizing and mining existing 
datasets to uncover or quantify cellular function.[30,31] This and 
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Figure 1. Workflow of engineering artificial tissue using information driven design for tissue engineering and regenerative medicine.
Figure 2. Cell behavior is influenced by microenvironmental cues provided by cell–cell interactions, the ECM, mechanical properties, and physical 
architecture.
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other biomedical data should be used to inform the decision-
making process when designing complex biological systems. 
Tissue engineers, for instance, recognize the importance of 
core proteins and glycoproteins (e.g., collagens, fibronectin, and 
laminin), proteoglycans (e.g., chondroitin sulfate, heparan) and 
glycosaminoglycans (GAGs) (e.g., hyaluronic acid) in directing 
cell behavior.[32] These critical elements work in concert to 
mediate cell adhesion and movement, morphology, differentia-
tion, and overall gene expression. ECM suprastructures modu-
late cell behavior through ECM/ECM receptor interactions via 
the presence of binding domains such as RGD in the case of 
fibronectin, GFOGER for collagen, and YIGSR for laminin.[33] 
Modification of materials with peptides mimicking these cell 
binding domains is a classic approach for promoting cell guid-
ance and has been used to achieve cell patterning. A major 
challenge lies in reducing the complexity of the ECM to a com-
bination of materials that is scalable, cost-effective, and most 
importantly, retains biological relevance for the task at hand. 
Several strategies for mimicking the ECM are later discussed or 
have been reviewed elsewhere.[34,35]
2.2. Biological Activity
The function of healthy tissue can be summarized as to support 
regular cell behavior while preventing irregular behavior. These 
functions, though clearly distinguished by tissue type, are gen-
erally regulated through balancing critical elements including 
cell population, ECM composition, or transmission of sign-
aling molecules. Furthermore, all tissues require transport of 
nutrients, waste, and information. Transport, which may occur 
passively through diffusion, or actively through energy-driven 
processes, is often facilitated in vivo by sophisticated networks 
of vasculature and lymphatic systems. Recreating these biolog-
ical networks is essential for the reconstruction of any tissue 
construct that supersedes the passive diffusive limit of oxygen 
(≈200 µm).[36]
ECM-affiliated proteins (e.g., syndecans), regulators (e.g., 
transglutaminases) and secreted factors (e.g., TGF-β, VEGF) 
play a significant role in regulating cell and tissue behavior. 
Increasingly, these factors are recognized as critical elements 
in designing biomaterials that retain functionality, particularly 
in promoting wound healing, repairing diseased tissues, and in 
stimulating vasculogenesis. Key considerations for designing 
materials include natural or synthetic affinity between the 
factors and the biomaterial surface or matrix, overall stability 
and spatiotemporal control, mode of delivery, and stimuli 
responsiveness.
Based on the above concepts, key aspects of biological com-
plexity that must be considered in designing biomaterials 
include the chemical composition, physical and mechanical 
properties, and the overall hierarchical organization that ena-
bles precise assembly of desired inert or biological components.
3. Information-Driven Materials Design
Traditional techniques for fabricating substrates in regenerative 
medicine, such as solvent casting and particle leaching, rely on 
processes that lack precise control over architecture and cellular 
composition.[37] Emerging micromanufacturing techniques aim 
to integrate computer-aided design or manufacturing (CAD/
CAM) to allow for the information that must be obtained using 
advanced imaging techniques to guide the materials design 
process. Beyond this approach, the design of next-generation 
biomaterials is predicted to further incorporate biological infor-
mation transfer at the single-cell level.[38] In combination with 
computational and statistical models, efficient designs that con-
sider aspects of anatomical hierarchy can be pursued.
3.1. Imaging
While standard biomaterials, for example, in the form of 
implants, are widely available today, personalized biomaterial 
development has not yet been fully embraced.[39] To recon-
struct individually designed tissue replacements, morpholog-
ical information of the original tissue is necessary. Computed 
tomography (CT) and magnetic resonance imaging (MRI) pro-
vide access to a series of 2D images, which may be used in the 
development or characterization of microtissues.[40,41]
Hollister, for example, used these two medical imaging 
techniques for designing a human mandibular condyle bone 
tissue[42] (Figure 3C). Computational topology design (CTD) 
and Boolean image techniques led to a 3D geometric model of 
the tissue harnessing information about the global anatomic 
and integrated architecture.[42] The calculated CAD data of the 
tissue geometry can be translated into a vector script and sent 
for microfabrication, which rebuilds individual scaffolds for the 
target tissue (Figure 3A). Alternatively, iCAT-CT (Xoran Tech-
nologies Inc.) data of a porcine periodontal defect have been 
used to inform the design of tissue equivalents.[43] To mimic 
the surface morphology, interfacial microchannels were added. 
After manufacturing the hybrid scaffold via STL (Surface Tes-
sellation Language) files, contrast agent and micro-CT was used 
to evaluate host adaption.[43]
An ultrathin tubular free-form structure was recently fab-
ricated, which provides sufficient mechanical flexibility. The 
modeling of the 3D structure in STL format of a bile duct is 
based on medical image data using MRI. 2D and 3D mag-
netic resonance cholangiopancreatography (MRCP) images 
were therefore taken of the tested rabbits for modeling as 
well as investigating the interconnection between the artificial 
scaffold and the native bile duct[44] (Figure 3D). Creating 3D 
models of living organs based on imaging can also be used 
in medical research[39] (Figure 3B). Markl and co-workers, for 
example, combined flow-sensitive 4D MRI with rapid proto-
typing technology and computational fluid dynamics (CFD) to 
investigate the gas flow in the human tracheas and bronchial 
tree.[45]
To date, MRI and CT are the most frequently used techniques 
for image-guided design of scaffolds in tissue engineering. 
However, combining different medical imaging techniques will 
provide even more detailed information. For example, with the 
help of endoscopy in combination with fluorescence imaging 
or confocal laser scanning systems, the tissue and its properties 
can be locally assessed with high precision. Positron-emission 
tomography (PET) or single-photon emission computed 
Adv. Mater. 2019, 1806898
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tomography (SPECT) makes it possible to analyze metabolic 
processes of tissues.[46,47] The images of the region of interest 
can be computationally transformed using CAD software and 
mathematical modeling.[48,49]
3.2. Omics-Inspired Materials Design
Classical approaches to biomaterial design rely heavily on a 
low-throughput trial and error methodology that has inevi-
tably led to a substantial number of scientific articles in the 
field, with minimal clinical successes. While a number of fac-
tors contribute to this disproportionate scientific output, some 
key technical challenges that have hindered progress in the 
field can now be addressed with the latest tools available to 
researchers.[38] These include cutting-edge advances in biology 
such as single-cell omics, data-reduction tools to aid in experi-
mental design and data analysis, and high throughput polymer 
libraries that facilitate rapid materials screening.
“Omics” is a neologism generally referring to the fields of 
biology focused on studying the totality of a major aspect of the 
cell (e.g., genome, proteome, and metabolome). More gener-
ally, the suffix “-omics” can be considered as “all constituents 
considered collectively” and has, with somewhat intemperance, 
made its way into the vernacular of many other disciplines (e.g., 
radiomics, video-omics). Understandably, the major success of 
the Human Genome Project has sparked interest in applying 
this approach to other disciplines. For instance, The Materials 
Genome Initiative was launched with the intent to create new 
materials-innovation infrastructure from discovery through 
deployment.[50] One outcome of this initiative is The Materials 
Project, which has the mission of combining informatics and 
materials science with recent advances in scientific computing 
to accelerate the discovery of new inorganic materials.[51] As 
a result, hundreds of thousands of materials now exist in the 
database to aid in designing electronics, batteries, and other 
inorganic compound-based structures. Importantly, workflows 
for computational materials science have been generated that 
may serve as a template for other tangential disciplines.[52]
The emerging materiomics approach in biomaterials design 
and development proposes using iterative materials synthesis and 
biological characterization cycles to unwind the complexity of mate-
rial property effects on biological systems.[38,53,54] Such an approach 
relies on the convergence of materials science and engineering, 
chemistry, data science, and biology to leverage the advances 
listed above. The term “biomateriomics,” originally defined by 
Cranford and Buehler, may be considered a materiomics approach 
to studying biological systems.[1] Several examples where such 
approaches may be leveraged to discover and/or engineer new bio-
material properties are discussed elsewhere in more detail.[1,38,54] 
We summarize a vision for how these approaches may be enacted 
through discussing proposed experimental design schemes.
Complex synthetic biological systems have two major com-
ponents: i) the biological, or “living”, and ii) the nonbiological, 
or “non-living.” As discussed, biological components have hier-
archies that enable function, while nonbiological components 
have an almost limitless design space that can be explored 
through materials selection and design. At the interface of these 
two components, i.e., “biointerface,” is a combinatorial library 
of possible interactions that achieve a coupled function.[54] 
Achieving a desired function requires great understanding 
about both the biological (e.g., cell behavior) and nonbiological 
(e.g., material properties) components, but also about how 
their interactions drive responses in the other. The pursuit of a 
holistic understanding of the interactome of these components 
is an emerging goal among researchers that is expected to drive 
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Figure 3. Imaging-based modeling used in the design of bioengineered scaffolds. A) Schematic workflow of imaging-based modeling. Adapted with 
permission.[39] Copyright 2010, Springer Nature. B) Using flow-sensitive 4D MRI to investigate the gas flow in the human traches and bronchial tree. 
Adapted with permission.[39] Copyright 2010, Springer Nature. C) CT and MRI were used for designing a human mandibular condyle bone tissue. 
Reproduced with permission.[42] Copyright 2005, Springer Nature. D) Modeling of the 3D structure in STL format of a bile duct based on medical image 
data using MRI. Adapted with permission.[44] Copyright 2017, American Chemical Society.
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advances in nanomedicine, medical device development, tissue 
engineering, and material science.[54]
Analogous to the way combinatorial chemistry has led to 
the discovery of new drugs and accelerated clinical outcomes, 
biomaterials development will benefit from rapid property 
discovery and biological assessment.[55] Key to the success of 
this approach is defining a concise parameter design space, 
targeted biomarker profiling, and limiting experimental scope 
(e.g., through implementing design of experiments (DOE)) to 
reduce the number of experiments that result in datasets that 
take years and highly sophisticated techniques to analyze. In 
combination with computational modeling, information-driven 
materials design offers a powerful approach that has the poten-
tial to produce materials with improved clinical function.[56]
A standard workflow for the next generation of biomate-
rials design may involve three major stages: screening, surface 
response, and optimization.[53] In the screening stage, par-
tial- or full-factorial design is implemented for high-throughput 
production of materials with varying parameters of interest. Typi-
cally, a base material (e.g., polyethylene glycol (PEG)) is selected 
that can easily be modified for high-throughput production and 
iteration. This library is then assessed for specific outputs of 
interest, such as driving a cellular response (e.g., live/dead assess-
ment, specific biomarker production, cell adhesion, etc.). At this 
stage, a subset of the original parameter selection will guide the 
second stage, referred to as “surface response,” where finer tuning 
of the material parameters can be explored with more complex 
output assessment. The final “optimization” stage involves a small 
number of designs that can be assessed for their functionality in 
the most advanced assays (e.g., in vivo animal testing).
Full characterization of the final design may involve high 
resolution genomics, transcriptomics, and proteomics. At each 
of these stage iterations, computational and statistical mod-
eling can be implemented to maximize efficiency. This and 
similar approaches have recently been implemented to identify 
polymers that are resistant to bacterial attachment,[57] optimize 
delivery of proteins for cardiac repair,[58] design zwitterionic 
polymer brushes for stem cell growth,[59] optimize seeding 
efficiencies for dermal scaffolds,[60] and predict cardiac repro-
gramming outcomes on biomaterials.[61]
While these approaches are promising for demystifying the 
relationship between biological components and synthetic sub-
strates, a number of challenges plague this area of research. 
These include lack of standards in characterizing biomaterials, 
parameterization of cell and material responses, validating the 
biomarkers used for assessing biological outcome, and managing 
the large datasets these types of experiments produce.[38,53,62] 
Standardizing reporting in bio–nano literature was recently 
covered, though establishing rigorous standards for biomate-
rials reporting is still warranted.[63] Material-biological property 
parameterization was also recently addressed.[62] Cellular param-
eterization includes characterizing cells through gene expression 
analysis and high-content imaging, while important material 
parameters include chemical composition and spatial organiza-
tion.[62] Implementing data-dimensionality reduction strategies, 
improved visualization tools, and more efficient machine-learning 
algorithms will be required to address the critical issue of man-
aging and analyzing large datasets.[64–68] An additional challenge 
remains in curating datasets that provide information in a robust, 
reproducible manner. A number of databases exist separately for 
materials scientists and biologists. Unifying the two has remained 
a significant challenge, however. Hebels et al. recently released 
the Compendium for Biomaterial Transcriptomics (cBiT), a first-
of-its-kind repository designed for researchers to search bioma-
terial-based transcriptomics data.[69] Efforts such as these are 
necessary for progress in this field, and the paucity of resources 
for understanding material–biological interactions will continue 
to impede progress. Developing mathematical models to under-
stand these interactions is critical, especially as the biotechnology 
sector enters “Industry 4.0,” which relies on the development of 
digital representations of products and processes to optimize their 
design.[62,70] This cannot be achieved without reliable, consistently 
annotated data repositories. Together, these efforts are aimed at 
providing resources and integrating a holistic approach toward 
understanding how materials and the biological components they 
interact with may be controlled for desired function.
4. Characterization and Validation of Biomaterials
4.1. Biomaterial Candidates for Micromanufacturing
There is a plethora of materials used in the micromanufac-
turing of biointegrative systems with various in vitro or in vivo 
applications. These materials are composed of metals, ceramics, 
macromolecules, or composites thereof. Apart from polymers 
and naturally derived materials, ceramic and metal materials 
have a long and successful history in dental and orthopedic 
applications that have been reviewed elsewhere.[71–73] Further-
more, there are many applications of biomaterials as medical 
devices that have been discussed elsewhere.[74,75] In contrast, 
herein, we will focus on emerging trends in the employment of 
macromolecular materials in tissue engineering with a specific 
focus on challenges associated with their validation and clinical 
translation (Table 2). Naturally occurring biomacromolecules 
are employed as biomaterials and are primarily composed of 
polysaccharides and proteins. They generally feature physi-
ologically relevant compositions, biocompatibility, abundant 
availability or bioinductive properties.[76,77] Synthetic macro-
molecules used in biomaterials applications are generally com-
posed of synthetic polymers, such a polyesters, polyurethanes, 
hydrogels, or acrylate-functionalized polymers. Synthetic mate-
rials often allow for more precisely controlled physical prop-
erties such as chemical composition, stiffness, degradability, 
and architecture, as well as the potential to elude the immune 
system.[14,76]
Adv. Mater. 2019, 1806898
Table 2. Key elements of biomaterials.
Key elements of biomaterials
• Precise control over material properties
An ideal biomaterial would allow for orthogonal control over physical char-
acteristics and biochemical composition with tissue appropriate properties.
• Tunable bioactivity
An idea biomaterial would have user prescribed bioinertness or bioinductive 
capacity depending on the intended application.
• Biodegradation
Tunable bioassociated degradability with definable kinetics and biocompatible.
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4.1.1. Synthetic Polymers
Polyesters are biodegradable, tend to be biocompatible, and 
have a long history of use in various in vivo applications, such 
as sutures. Common polyester biomaterials are poly(lactic acid) 
(PLA), poly(lactic-co-glycolic acid) (PLGA), poly(ε-caprolactone) 
(PCL), and poly(lactide-co-caprolactone) (PLCL). These poly-
mers are frequently electrospun to create fibrous mats used for 
tissue engineering.[78–80] While electrospun mats are common 
in tissue engineering, there are subtler biological implica-
tions, namely the potential for protein fouling on implanted 
scaffolds to initiate an adverse immune response that need to 
be addressed. Kostina et al. are addressing this issue by modi-
fying the surface of PCL fibers with nonfouling coatings.[81] 
Our lab has leveraged the chemical functionality of polyes-
ters to create electrospun biphasic fibers of PLGA derivatives 
to direct the attachment of cells on microfibers.[82] Polyesters 
are also favored for their inherent degradability, which occurs 
through acid- or base-catalyzed hydrolysis of the ester back-
bone. For PLGA, this results in the release of metabolites, i.e., 
glycolic acid and lactic acid, which can be cleared by the host. 
The degradation rate can be controlled by the ratio of lactic acid 
and glycolic acid blocks, as well as blending PLGA with other 
polymer derivatives.[83,84]
Given that polyesters are thermoplastic, they can easily be 
incorporated into melt extrusion or filament based 3D printing 
systems.[85–87] Generally, using these techniques larger fibers 
(>100 µm) are produced, which may not be desired for certain 
tissue engineering applications since features would ideally be 
subcellular (<20 µm). Recently, Wunner et al. developed a melt-
electrospinning technique to create porous scaffolds comprised 
of 20 µm diameter fibers.[88] Our lab has recently reported an 
electrospinning-based jet writing technique that allows for 
3D printing of scaffolds comprised of very fine PLGA fibers 
(≤10 µm diameter) that were highly successful in repairing a 
cranial defect in a mouse model.[89] Furthermore, polyesters are 
amenable to other manufacturing techniques such as micro-
sphere sintering, solvent casting, and phase separation.[90] 
Other efforts involved similar techniques in combination with 
a sacrificial template technique to create porous PLGA scaffolds 
with multilength scale features for spinal cord injury repair.[91] 
Beyond polyester materials, high-resolution 3D printing of 
polyelectrolyte solutions can be used to create tissue scaffold 
structures. These inks are combinations of polyanions like 
poly(acrylic acid) (PAA) and polycations like poly(ethylenimine) 
(PEI), or poly(allylamine hydrochloride) (PAH) that can be 
written into structures with filament sizes as small as 1 µm.[92,93]
Additionally light-based polymerization of synthetic poly-
mers is attractive for the manufacturing of complex material 
systems because of its potential for ultrafine resolution and 
spatiotemporal control. Various acrylates or acrylate-modified 
polymers are used for their advantageous photopolymeriza-
tion. Furthermore, commercially available photoresists like 
OrmoComp have been used in conjunction with multiphoton 
polymerization to create ≤1 µm sized features, which can 
be selectively functionalized to guide cell attachment.[94] 
This material is a hybrid organic/inorganic molecule com-
posed of a silicon-based component and photopolymerizable 
component.[95]
Generally, photopolymerization chemistries rely on a photo-
initiator that forms radicals upon illumination, which polymer-
izes a monomer that possesses multifunctional crosslinkers.[96] 
Various additives, including other polymers, can be added to 
tune solution properties critical for 3D printing.[96] Photopoly-
merization techniques are widely applied to hydrogels and 
other polymers for tissue engineering applications and have 
been reviewed in details elsewhere.[96,97] Hydrogels make up 
a large class of water-laden polymer networks that are typi-
cally biocompatible and have physiological stiffnesses similar 
to many tissues. These poly mer networks can be crosslinked 
via covalent bonds (chemical hydrogels) or noncovalent (phys-
ical hydrogels) molecular interactions.[97] PEG is a ubiquitous 
hydrogel in tissue engineering that is highly bio-inert, yet ame-
nable to dramatic chemical modifications to create a diverse 
array of functional PEG derivatives.[98] PEG can be functional-
ized to be photoreactive, with PEG di-acrylate (PEGDA) and 
PEG methacrylate (PEGMA) being the most common candi-
dates.[97] When 3D printing hydrogels, there are many consid-
erations ranging from fluid properties, nozzle design, and the 
choice of crosslinking method (physical vs chemical) to solu-
tion properties, such as shear thinning or thickening, viscosity, 
and time to gelation. Gaining deeper control over these solu-
tion properties, especially those occurring dynamically during 
gelation/crosslinking is key for the future of 3D printing hydro-
gels.[97] High-resolution hydrogel structures have been demon-
strated by Richter et al., where 1 µm sized PEGDA structures 
were created to engineer protein-repellant portions of the afore-
mentioned microstructures.[94]
Outside of photopolymerization and 3D printing, PEG can be 
formed into monolithic gels using other crosslinking methods 
such as enzymatic crosslinking of functionalized PEGs. These 
gels can contain relevant cell binding motifs and biodegradab-
able linkages to create biochemically relevant material sur-
faces that have been shown to be dramatically influence cell 
behavior.[99–101] Recently, advances have been made to improve 
encapsulation and spatial localization of single cells in func-
tionalized biodegradable PEG microspheres with the potential 
to study single-cell behavior in controlled 3D niches.[102] Addi-
tionally, PEG has been demonstrated to be incredibly versatile 
and amenable to modification with various GAGs to produce 
GAG composites with tunable properties, which offers a poten-
tial route to the critical role of these polysaccharides in ECM 
biology (reviewed elsewhere).[103] Other bioinert hydrogels used 
in tissue engineering applications include poly(2-hydroxy ethyl 
methacrylate) (PHEMA), poly(acrylamide) (PA), and poly(N-
isopropyl acrylamide) (PNIPAAm) and have been discussed 
elsewhere.[37] While hydrogels may give rise to precise control 
over physical parameters like stiffness and degradability, many 
synthetic hydrogels lack physiologically relevant architectural 
motifs, such as fibril structures, which in part gives rise to 
interest in utilizing naturally derived materials.[14]
4.1.2. Naturally Derived Biomacromolecules
Protein-based biomaterials include, for example, collagen, 
fibrin, laminin, fibronectin, and elastin. Examples of poly-
saccharide-based biomaterials include alginate, chondroitin 
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sulfate, heparin sulfate, chitosan, and hyaluronic acid. Virtu-
ally all of these materials, either alone or in combination with 
another natural/synthetic material, have been processed into 
tissue scaffolds using electrospinning.[104–107] While traditional 
electrospun tissue scaffolds recapitulate the fibril structure 
of the ECM, they tend to be dense, relatively thin, difficult to 
handle, and are difficult to produce with higher order, organ-
ized architecture. Other traditional manufacturing techniques 
such as freeze drying, phase separation, and gas foaming 
techniques have been used with proteinaceous materials like 
gelatin and collagen to create porous scaffolds.[108–111] Some of 
these scaffolds may display ideal levels of porosity, but still lack 
precise control over microscale features and their hierarchal 
organization.
Furthermore, many of these biomaterials, like alginate and 
collagen, naturally form hydrogels that can be incorporated 
into 3D printing techniques. These systems tend to be more 
cell-compatible than synthetic 3D printing solutions; how-
ever, high- resolution 3D printed structures using naturally 
derived materials can be challenging. Nevertheless, recent 
advances have been made in 3D printing of collagen scaf-
folds; however, these scaffolds have relatively large printed 
features (>100 µm) composed of smaller collagen fibrils.[112] 
Collagen is widely used because of its innate propensity to 
autopolymerize in vitro and form hydrogels composed of phys-
iological relevant fibril architecture. This simultaneously poses 
a drawback, because subtle changes in solution properties 
like temperature or concentration can alter the properties of 
the resultant collagen hydrogels. Beyond proteins, an exciting 
technique for producing DNA-based materials with high-pre-
cision is DNA origami assembled from short complementary 
oligonucleotides.[113]
The potential benefits of naturally derived materials in 
tissue engineering may include their relative abundance, 
their biochemical relevance, their biocompatibility, their 
inherent degradability, and their bioinductive capacity. How-
ever, many of these materials are not mechanically robust 
and require secondary crosslinking to stabilize them prior 
to cellularization. Furthermore, as a result of various phe-
nomenological assembly processes of different naturally 
derived materials, they generally lack orthogonal control 
over physical properties such as stiffness, ligand density, and 
architecture.[114]
4.1.3. Composites and Materials’ Complexity
Fundamentally, organs may be considered to be composite 
materials composed of complex tissues and interfaces where 
the ECM acts to direct cell fate with multifaceted cues that 
hinge on their material properties. To engineer tissue at the 
organ level, multiphasic materials systems are necessary. 
Major challenges associated with tissue engineering include 
overcoming poor mechanical stability of natural materials/
hydrogels, recapitulating complex tissue characteristics like 
mechanical gradients, engineering the multiphase architec-
ture of tissues, and producing tissue scaffolds that recapitulate 
functional processes like nutrient transport or toxin filtration. 
Recent developments have been made to 3D print composite 
materials such as a mechanically robust PEG/alginate hydrogel, 
of which both systems are historically weak.[115] A mechanically 
complex tissue interface to recapitulate is that of the enthesis 
(where tendons and ligaments anchor to bone). Mechanical 
integrity at this interface is critical for orthopedic implants; 
however, the transition from soft tissue to stiffer bone (or bone 
replacement) makes this a very difficult problem to solve.[116] 
The skin is another organ composed of distinct layers with 
unique biological roles and architectures; hence, researchers 
are leveraging innovative approaches to creating multiphasic 
systems for the treatment of full thickness wounds, as well 
as the creation of representative in vitro skin equivalents that 
allow for long term culture (6 weeks) with immune and neu-
ronal fractions for investigative studies.[117,118]
Furthermore, creating functional and integrable vasculature 
networks remains a huge challenge for tissue engineering. 
Novel approaches have been taken to 3D print complex vas-
cular networks out of combinations of a synthetic material like 
Pluronic F127 and methacrylated gelatin (GelMA) with and 
without cells.[119] Considering broader applications, recently 
Gou et al. demonstrated an innovative approach to incorpo-
rate functional nanoparticles into a highly ordered 3D printed 
PEGDA hydrogel systems with to create a cell-free detoxifica-
tion scaffold.[120] These examples underscore the necessity of 
creating composite biomaterial constructs, as the research field 
intends to engineer more complex tissue scaffolds.
4.2. Characterization and Validation of Bioinstructive 
Material Systems
Biomaterial systems that aim to recapitulate the hierarchal bio-
logical features found in vivo become increasingly difficult to 
characterize. Some characteristics such as biocompatibility are, 
in part, defined by regulatory agencies. For instance, the U.S. 
Food and Drug Administration (FDA) utilizes the International 
Organization for Standardization (ISO) standards to assess 
risk and biocompatibility (ISO 10993 standards), which is sub-
categorized into various toxicities, hemocompatability, degra-
dation, sensitization, and implantation. It is critical to note that 
the FDA regulates devices, not materials; hence, for regulatory 
agencies and researchers, all considerations of the appropri-
ateness of a material are application dependent. Additionally, 
the comprehensive approach necessary for assessing safety 
and biocompatibility of a medical device seeking regulatory 
approval is challenging to achieve for academic researchers; 
however, some of the subcategorized tests laid out in the 
FDA guidelines may be useful in directing academic studies 
and help to solidify good research practices. Hence, it could 
be beneficial to assess the translational potential of a biomate-
rial during early technological development with the regulatory 
guidelines in mind. Beyond biocompatibility, characterizing 
material properties like topology and stiffness in a transla-
tionally validated context becomes very difficult as well. There 
are some standard characterization methods such as those 
put forth by the American Society for Testing and Materials 
(ASTM) for biomaterials systems (F2150-13 and STP1173); 
however, complex composite materials, especially macromo-
lecular systems, may not strictly adhere to the requisites of 
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those tests.[121] Yet, as previously discussed, it is well accepted 
that cell behavior largely hinges on these inherent material 
properties (physical and biochemical). This underscores the 
need for deeper investigation into cells in 3D systems and 
approaching the characterization of biomaterials with stand-
ards and good practices in mind.
4.2.1. Characterization of Physical Properties
The stiffness or compliance of a material is thought to direct 
cell fate, which is well accepted using 2D models but becomes 
increasingly complex to assess in 3D systems. Depending on 
the inherent properties and size of a biomaterial, the characteri-
zation of stiffness may involve rheological techniques, uncon-
strained compression testing, tensile testing, contact model 
guided indentation (nanoscale to macroscale) or via ultrasound 
elastography.[122–126] In all cases, the underlying assumptions 
and limitations of the model and method chosen should be 
carefully considered, which may highlight the need for new 
models to be adapted for particular biomaterial systems. This 
is especially important when biomaterials in vitro are compared 
to the native, in vivo, tissue which often cannot be done directly 
considering different methodologies needed for each setting. 
Stringent adherence to good practices, as well as differences in 
methodologies and test conditions are critical to address when 
interpreting and comparing the results of mechanical testing. 
Furthermore, any bulk material properties offer little informa-
tion as to the cell-scale heterogeneity of mechanical proper-
ties, especially as the cells engage in a dynamic modulation of 
their 3D biomaterial environment through physical manipu-
lation and chemical degradation. Using a particularly elegant 
approach, Juliar et al. assessed angiogenic sprouting events in 
fibrin gels, in situ and correlated them to the mechanical prop-
erties at both the cell scale and bulk length scale using laser 
tweezer microrheology and bulk rheology, respectively.[127] This 
study revealed a significant amount of microscale stiffness het-
erogeneity surrounding sprouting events that changed over 
time. There was a general trend toward increased bulk stiffness 
over time likely associated with remodeling by the stromal cells. 
Ultimately, this work underscores the value in taking a more 
rigorous approach to assessing mechanical properties associ-
ated with biological phenomena, in situ and at various length 
scales.
Surface topography is known to influence cell behavior, 
as has been shown with various well-defined engineered 
2D surfaces.[128] However, nanoscale topography under 
physiological conditions in 3D is very difficult to assess in situ 
considering the hydrated state of many biomaterials. Liquid-
phase atomic force microscopy (AFM) can be applied on rela-
tively flat surfaces; however, many biomaterials have higher 
order, microscale topography that precludes the use of AFM-
based assessment of nanotopography. Future advancements in 
environmental scanning electron microscopy (ESEM) or cryo-
SEM techniques may address some of these shortcomings, 
and recent advancements in preserving aqueous, bio-based 
surfaces for imaging in ultrahigh vacuum can be employed to 
better assess the aqueous phase topology of biomaterials.[129] 
Additionally, advancements in ultrahigh resolution fluorescent 
imaging technologies are helping to shed light on focal adhe-
sion dynamics in 3D systems.[130] Advances in fluorescent 
microscopy will help to bolster our understanding of how cells 
interact with material topology in 3D.
Characterizing and engineering the biochemical compo-
sition of a tissue are also a nontrivial pursuit, in large part 
because tissues are compositionally diverse owing to the hun-
dreds of different proteins and polysaccharides that make up 
a single tissue.[131] Often, there is a gap in knowledge about 
the complete composition of a target tissue and most impor-
tantly, which of the proteins are critical to facilitate the tis-
sue’s primary function at the cellular level. This gap in 
knowledge gave rise to a significant effort from a Swedish-
based program in 2003 known as The Human Protein Atlas 
(HPA).[132] The HPA has set out to map every protein from 
the cellular to the organ level with a multiomics approach 
using transcriptomics, antibody-imaging, and mass spectrom-
etry proteomics.[133,134] Efforts like these will give engineers a 
target to aim for, so that scaffolds and materials can be more 
intelligently designed.
4.2.2. Validation and Challenges
Establishing functional benchmarks of in vitro systems against 
native tissues is another nontrivial endeavor. However, defining 
translationally relevant functional readouts is key to the success 
of any in vitro technology to ensure that different approaches 
can be benchmarked against one another. For instance, a bio-
assembly method of producing primary hepatocyte spheroids 
has led to the ability to maintain viable, metabolically active, 
functional hepatocytes, and translationally relevant cultures for 
up 5 weeks, which is not possible to do using conventional 2D 
culture methods.[135] In 2017, AstraZeneca and Genentech Inc. 
used primary hepatocyte spheroids to demonstrate an improve-
ment in hepatotoxicity prediction power of this 3D model com-
pared to 2D methods of culturing hepatocytes.[136] In addition 
to potential strides in preclinical drug safety assessment, the 
knowledge gained from understanding how the 3D microen-
vironment of a liver spheroid improves primary hepatocyte 
viability and function could potentially inform the next steps to 
recreating larger scale functional liver mimics for tissue engi-
neering applications.
In cardiac engineering, readouts for tissue maturation 
include conduction velocity, force generation, and calcium han-
dling.[137,138] Recent advances by Ronaldson-Bouchard et al. 
represent the state of the art in maturing iPSC-derived cardi-
omyoctes in vitro.[139] While these and similar constructs will 
likely be first used to improve preclinical toxicity assessment, it 
stands to reason that the deeper understanding of growing car-
diomyoctes in engineered 3D in vitro systems will glean critical 
details for how to better mimic and produce full scale tissues 
for implantation.
To date, there is a vast range of potential material systems 
for any given biological question. To better navigate this vast 
space, omics approaches are beginning to be applied to bio-
materials development. For example, computational models 
can be employed to assess the critical functions of bio material 
systems and thereby more intelligently guide their design and 
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implementation.[38,53] Hence, an omics approach to rationale 
biomaterials design should be employed.  Additionally, to 
begin to weigh one material against another, head-to-head 
comparisons of various 3D biomaterial systems need substan-
tial investment. Further benchmarking of biomaterial systems 
against one another with more clearly defined characterization 
methods will help lead better design of biomaterials systems.
Ultimately, for a tissue scaffold to be clinically translatable it 
has to: i) demonstrate efficacy and validation in a tissue appli-
cation, ii) meet rigorous standards for safety, iii) be commer-
cially manufactured according to Current Good Manufacturing 
Practices (CGMP), and iv) be economically viable. Many acel-
lular scaffolds have been successful in the clinic; however, these 
challenges pose significant hurdles for cell-based therapies 
leading to fewer successes.[140] Cell-related challenges in tissue 
engineering have been outlined extensively elsewhere.[141] 
Regu latory pathways may change for acellular compared to cell-
based scaffolds, depending on the country, market of interest 
and intended medical application. In the United States, cell free 
scaffolds may be treated as medical devices and regulated by 
the FDA’s Center for Devices and Radiological Health (CDRH). 
If a tissue scaffold is cell-laden, then it may be characterized 
as a biologic and regulated by the FDA’s Center for Biologics 
Develo pment and Research (CBER). Cell-based systems are 
subject to additional scrutiny for various reasons, including 
increased safety concerns and the need to translate varying aca-
demic research practices into strictly controlled manufacturing 
processes that adhere to CGMP, which stresses the importance 
of control from raw materials all the way through reliably gener-
ating a consistent, characterized product at a commercial scale 
with excellent quality control.[140–142] Human pluripotent stem 
cells (hPSCs) have been an exciting cell source for cell-laden 
tissue scaffolds; however, their clinical translation is hindered 
by the choice of source (allogenic or autologous), the need to 
produce commercial scale quantities of cells, the need for strict 
control over differentiation to create pure cell populations with 
the desired phenotype/function, and the ability to do this in 
a cost-efficient manner (extensively reviewed elsewhere).[142] 
Considering all of the hurdles associated with the clinical 
translation of tissue scaffolds (efficacy, validation, safety, com-
mercialization, CGMP, and cost-efficiency), it becomes clear 
that a data driven approach to the rationale design and imple-
mentation of new biomaterials systems is required through 
close collaboration between engineers, health professionals, 
bioinformaticians, fundamental scientists and commercially 
minded people alike.
5. Scaffold Micromanufacturing
5.1. Micromanufacturing Techniques
In engineering complex biological systems, material properties 
may be considered input parameters and biological outcomes 
the output parameters. An aspect of information-driven design 
that is necessary for reliable experimental interpretation, then, 
is precise knowledge of input parameters. In other words, the 
material properties must be precisely defined. Control over 
these properties has advanced in recent years through the 
advent of micro- and biofabrication techniques that enable the 
precise placement of materials and biological components. 
These are promising as tools for advanced in vitro models for 
regenerative medicine applications.[143] Multiple approaches 
have been explored for the combination of materials and cells. 
Classic tissue engineering involves fabricating a scaffold cells 
grow and proliferate throughout. Modern biofabrication ena-
bles controlled deposition of cell-laden bioinks of synthetic or 
natural matrices. Recently, Moroni et al. introduced the spatial 
resolution/time for manufacturing (RTM) ratio as a quantita-
tive metric for assessing fabrication efficiency, which we use 
here to compare techniques.[144] In this section, we discuss 
advanced fabrication approaches that are being developed for 
acellular scaffold production (Table 3).
In general, 3D printing has been utilized across multiple 
industries for rapid prototyping for multiple decades.[145–147] 
Classic 3D printing refers to the process whereby a jet of 
binder is directed at a powder bed to create predefined pat-
terns. With the rapid and widespread adoption of 3D manu-
facturing, dozens of other “3D printing” techniques have 
emerged. These include light-based approaches such as ste-
reolithography (SLA), digital projection lithography (DLP), 
continuous liquid interface production (CLIP), and direct laser 
writing (DLW), ink or filament-based printing approaches such 
as fused deposition modeling (FDM), extrusion printing, direct 
ink writing (DIW), and inkjet printing, and electrospinning 
techniques.[143,148–150]
Extrusion printing, sometimes referred to as “ink-based 
printing” encompasses additive manufacturing approaches 
that result in the 3D deposition of materials such as filaments 
and droplets using computer-aided design that allows for arbi-
trary structure design.[93,149] These materials may be subject 
to thermal, pneumatic, light-based, or mechanical treatment 
during deposition or in postprocessing. FDM was the ear-
liest implementation of filament printing, whereby thermo-
plastic filaments are passed through a heated nozzle onto a 
build platform and structures are assembled layer-by-layer as 
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Table 3. Key elements of micromanufacturing techniques.
Key elements of micromanufacturing techniques
• Resolution and scalability
Achieving hierarchical design of tissue requires patterning of molecules 
at sub-micrometer scale while simultaneously being able to fabricate 
structures over large areas and build volumes.
• Speed
Iterative processing for material design requires rapid prototyping.
• Ease-of-use
Ideal techniques would allow for use by nonexperts, decrease user-error, 
and diminish time required for optimizing fabrication parameters.
• Cost
Cost for both the micromanufacturing apparatus and consumable 
materials should be minimized.
• Materials compatibility
A wide range of synthetic and natural materials and biological 
components such as live cells would be able to be processed either 
simultaneously or sequentially.
• Translational potential
Ideal micromanufacturing techniques will facilitate commercial and 
clinical translation.
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they cool below their glass transition temperature. FDM has 
been applied for creating microfluidic devices, tablets, and 
implants with a wide range of materials, including ABS, PLA, 
PCL, PMMA, and PVA.[151,152] FDM dominates the desktop 
3D printer market space due to the available materials, ease 
of use, and relatively efficient printing (RTM ratio ≈ 1).[143] In 
creating biomedical devices or other biomaterials, there are 
however many limitations to FDM such as a relatively large 
feature minimum feature width (≈200 µm), and an overall 
limitation in materials that can be printed, many of which 
are not biocompatible or suitable for most tissue engineering 
applications.
In the context of producing acellular scaffolds, printing typi-
cally relies on soft materials such as polymeric or particulate 
matter that exhibit steady flow during the deposition process 
but achieve stability (e.g., through gelation or cooling below the 
glass transition temperature) upon delivery. Emphasis is placed 
on identifying conditions in which starting materials are print-
able, through optimizing parameters such as viscosity, thermal 
conductivity, and shear-thinning properties. Printing of cell-
laden “bioinks” is often referred to as “bioprinting” and enables 
the precise placement of cells either alone or within a support 
structure. An added layer of complexity may be explored with 
dynamic materials (i.e., materials that change over time or in 
response to a stimulus), often referred to as “4D printing.”[153] 
Several excellent reviews have discussed ink-based printing 
for tissue engineering.[4,37,149] Overall, biomanufacturing is 
trending toward faster printing speeds, improved resolu-
tion, and use of sophisticated materials. These advancements 
emerge through the development of novel materials and manu-
facturing approaches that enable complex designs that may 
recapitulate native in vivo tissues.
5.2. Light-Based 3D Printing
The major light-based printing methods include SLA, CLIP, 
and DLW.[154] These methods are based on the principle of 
bathing a photopolymerizable resin with light at a specific 
location to generate a CAD structure.[149]
While SLA, DLP, and CLIP allow for relatively efficient 
printing (RTM ratios ≈0.5–2) and enable large build volumes, 
direct laser writing at the nanoscale is achievable using two-
photon polymerization (2PP).[144,154] 2PP relies on a photoini-
tiator that simultaneously absorbs two near-infrared photons 
to generate free radicals for initiating polymerization within a 
monomer reservoir, enabling unprecedented lateral resolutions 
of ≈100 nm.[155] Most structures generated using this method 
therefore require photosensitive polymers and initiators, which 
have the potential to be toxic.[156] Commercially available cyto-
compatible photoinitators include certain Irgacure formula-
tions and dye-amine combinations (e.g., Rose Bengal dye with 
amine as a coinitiator).[96] One major challenge within light-
based 3D printing methods has been exploring multimaterial 
printing, as it is typically difficult to alter the composition of a 
polymer reservoir during printing.
Another challenge lies in patterning multiple materials or 
ECM components at very small length scales.[157] As 3D printing 
techniques have emerged, a greater emphasis on spatially 
patterning more advanced structures with equal resolution to 
2D approaches has evolved.
The first example of patterned ECM deposition in 3D using 
2PP was achieved by Klein et al.[158] Here, a protein-repellent 
PEG-DA PETA polymer framework was subsequently decorated 
with blocks of Ormocomp, an inorganic–organic polymer con-
taining siloxane linkages, that facilitated fibronectin binding. 
This sequential construction of protein-binding structures on a 
protein-repellent background enabled selective cell attachment 
that has since been applied for cell elasticity measurements.[159] 
A potential limitation to this approach is the binary nature of 
the protein attachment that limits control over types or amounts 
of proteins attached. Spatial control over the scaffold surface 
chemistry was introduced via a multistep process involving a 
two-photon-triggered cycloaddition whereby an Ormocomp 
scaffold first undergoes silanization to generate photoactivat-
able dienes, is then irradiated in the presence of protein–ligand 
dieonophiles with a femtosecond pulsed laser, and then biocon-
jugated with fluorescently labeled proteins[158,160] (Figure 4A–C). 
This strategy enables more selective attachment of specific 
moieties to the surface but is laborious and requires extensive 
processing. Another innovation relates to specific protein place-
ment through introducing photoresists that are either protein 
adhesive, repellant, or selective[94] (Figure 4D). In a step-wise 
process, a protein can nonspecifically adhere to the first resist 
and then a second protein can be conjugated to the selective 
resist following an activation strategy similar to the previ-
ously described approach (Figure 4E). This strategy results in 
the selective 3D patterning of multiple ECM components and 
was subsequently used to explore cell–ECM interactions on 3D 
structures (Figure 4F).
5.3. Toward 3D Electrojetting
Electrojetting is a process whereby polymer fibers may be pro-
duced through the use of electrostatic forces. A high voltage 
source feeds a direct current with a certain polarity into a 
poly mer solution or melt placed in a syringe with a constant 
flow rate. Grounding the collector leads to an electric field 
which stretches the polymer solution toward the collector. At a 
certain critical voltage, the electric stress increases sufficiently 
to distort the droplet into a conical shape creating the so-called 
Taylor cone. When the electric field strength exceeds the sur-
face tension of the solution, a fluid jet is accelerated toward 
the collector. By traveling through the surrounding gas phase, 
the solvent of the jet evaporates and leads to the deposition 
of a solid polymer fiber on the grounded collector. During jet 
propulsion toward the ground electrode, a bending or whip-
ping instability develops resulting in an oscillatory circular 
deflection of the jet.[161,162] Finally, a polymer fiber is deposited 
at the ground electrode as a nonwoven mat. Nowadays, a wide 
range of natural materials, biodegradable, and nondegradable 
synthetic polymers can be used to produce fibers in high-
throughput via this process.
In the last 25 to 30 years, the interests of using fibers for 
tissue engineering applications has increased. Due to high 
porosity and microtopography, nonwoven fiber mats are often 
considered to be structurally similar to the native ECM.[163]  
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Several research groups use electrojetted fiber mats to mimic 
the ECM for bone, skin, nerve, and vascular tissue engineering.
Nevertheless, the 2D electrospun scaffolds with randomly 
oriented fibers are limited in their application. Much research 
is therefore focused on orienting the fibers by applying appro-
priate collectors. Chang’s group used a cylindrical collector 
with equally spaced circular protrusions to yield a fibrous tube 
with patterned architectures (Figure 5A). They demonstrated 
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Figure 4. Multiphoton polymerization for production of spatially patterned materials. A–C) PEG-DA/PETA scaffolds are decorated with Ormocomp. 
Reproduced with permission.[158] Copyright 2011, Wiley-VCH. D,E) Strategies for selective patterning of proteins using selective patterning chemis-
tries or sequential deposition of protein repellent, selective, and adhesive polymers. F) Mouse fibroblast (NIH-3T3) cell shows preferential binding 
to fibronectin over vitronectin on scaffolds made using approach shown in (E). D) Reproduced with permission.[160] Copyright 2013, Wiley-VCH. 
E,F) Reproduced with permission.[94] Copyright 2016, Wiley-VCH.
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the production of 3D fibrous tubes with different diameters, 
lengths, and various cross-section shapes made of polycaprol-
actone (PCL) and PLA.[164] However, the deposition of the fibers 
was still random with pore sizes less than 20 µm in spite of 
their directionality.[165]
Pursuing a different technological approach, bicompart-
mental and biodegradable PLGA fibers were produced by using 
electrohydrodynamic cojetting.[82] Each fiber was composed of 
two distinguishable compartments, which can be selectively 
surface modified.[82,166] By using aligned multicompartimental 
microfiber scaffolds as templates for spatioselective azide–
peptide immobilization, a 2D cell culture substrate for guided 
cell adhesion of fibroblasts was designed (Figure 5B).[82] The 
challenge is now to bring these microstructures into the third 
dimension, requiring stabilization of the migration path of the 
jet. Additive patterning of materials for applications in biotech-
nology, sensors[167] or printed electronics has stimulated the 
development of different techniques related to high-resolution 
electrojet-printing, such as pyroelectrodynamic printing or 
other electrodynamic processes.[168] One example is near-field 
electrospinning (NFES).[169] By setting the working distance 
between the spinneret and fiber collector to a position before 
the onset of the whipping instability, a predictable location con-
trol for the deposition of fibers is possible.[170] As the needle 
to collector distance is fixed to 500 µm–1 mm, the solvent in 
the polymer jet may not have sufficient time to fully evaporate 
and may remain liquid after deposition.[171] By adding a com-
puter- assisted x–y translation stage the fiber gets mechanically 
stretched, leading to thinner fibers with oriented deposition.[172] 
Zhou et al. investigated the effect of various parame ters, such 
as working distance, flow rate, and stage speed on the mor-
phology of PCL fibers and sugar-PCL core–shell fibers with 
similar microstructures to neuronal and muscle tissues.[170] 
They fabricated high-resolution PCL scaffolds with controlled 
micrometer scale patterns and multilayer scaffolds with varied 
coiled pattern as shown in Figure 6A.[172] Nevertheless, the 
height of the scaffolds produced with NFES is limited by the 
short working distance.
Compared to most other electrospinning techniques, melt 
electrospinning is a solvent-free but heat-intensive technique. 
Melting the polymer in the supply zone to 80–300 °C and 
allowing sufficient cooling of the filament over a relatively long 
travel distance inhibits spin bonding that would create non-
woven fiber mats.[173] Brown et al. and Hochleitner et al. an 
elegant melt electrospinning-based direct writing approach. 
By combining a computer-controlled translating stage collector 
with the melt electrospinning setup allows the fabrication 
of orientated PCL structures over large areas.[173,174] Detailed 
analysis of process parameters such as electrical field strength, 
flow rate, and spinneret geometry resulted in highly controlled 
filament deposition. Layering sub-micrometer-sized fibers 
over each other resulted in structures with different grid sizes 
(Figure 6C) up to a height of 1 mm. Through a computer-
based simulation to keep the electrostatic force at a constant 
level while varying the working distance, a height of 7 mm was 
achieved.[88] In vitro cell culture studies showed good adhesion, 
growth, and differentiation of primary human mesenchymal 
stromal cells (hMSCs), human periodontal ligament (hPDL), 
and mesenchymal precursor cells (Figure 6B).[88,174]
Even though melt electrospinning is a solvent-free process, 
the high temperature limits the use of many biodegradable poly-
mers and biological materials, such as proteins, used in tissue 
engineering and regenerative medicine.[175,176] Additionally, 
cells cannot be directly printed using melt electrospinning.[177]
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Figure 5. Various scaffold productions using electrospinning. A) Illustration processing fibrous tubes using 3D columnar collectors with patterned 
architectures. Adapted with permission.[164] Copyright 2008, American Chemical Society. B) Spatial controlled peptide immobilization onto PLGA fiber 
scaffolds for selective cell guidance. Reproduced with permission.[82] Copyright 2009, Wiley-VCH.
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5.3.1. The 3D Jet Writing Process
An alternative strategy to control the deposition of electro 
spun fibers is based on manipulating the electric field. This 
often involves designing a grounded collector in the form of 
drums,[178] rings,[179] or poles.[180] Our lab recently presented 
a new method, termed 3D jet writing, to control the bending 
and whipping instability during jet propagation by applying a 
secondary electric field (Figure 7A).[89] The outward directed 
jet movement was suppressed by a ring electrode, which cre-
ated an electric potential well and reversed the direction of the 
electric field toward the center of the circular ring. Combining 
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Figure 6. Various oriented scaffolds fabricated with different 3D electrojetting techniques in combination with a computer-assisted x–y translation stage. 
A) Large volume scaffolds after seeding with hPDL cells and incubation in vitro. Adapted with permission.[88] Copyright 2018, Wiley-VCH. B) Highly 
ordered fiber architectures produced via electrospinning writing (MEW). Reproduced under the terms of the CC-BY 3.0 Creative Commons Attribution 
license (https://creativecommons.org/licenses/by/3.0/).[174] Copyright 2015, The Authors; published by IOP Publishing Ltd.
Figure 7. Scaffolds fabricated using 3D jet writing. A) 3D jet writing setup with computer simulations of the electric potential. B) Tessellated scaffolds 
structures of different geometries manufactured by 3D jet writing. C) hMSC culture on PLGA scaffolds in vitro after incubation with fibronectin. D) 3D 
scaffolds regenerated bone tissue on a defect mouse skull in vitro. A–D) Adapted with permission.[89] Copyright 2018, Wiley-VCH.
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the stable polymer jet with a computer-assisted x–y-stage 
allowed precise patterning of biodegradable PLGA fibers into 
open-pore structures in different shape and sizes as shown 
in Figure 7B. Human mesenchymal stem cells (hMSCs) were 
cultured on fibronectin-coated gridded scaffolds and filled the 
entire free volume of the 500 µm pores after three days of cul-
ture (Figure 7C).[89] The cell density was 1.4 × 106 cells per mm3 
PLGA, seven times higher than reported elsewhere.[181] Addi-
tionally, maximum cell–cell contact and differentiation toward 
an osteogenic lineage were determined. In vivo studies of 
attaching a cellularized scaffold on user-defined defect areas 
affected bone tissue regeneration while maintaining cell–cell 
interaction (Figure 7D).
Due to the precise deposition of the fibers at room 
temperature, 3D jet writing establishes a physiologically rel-
evant 3D culture platform. Even though the system is still 
solvent based, it is open for further materials as well as water-
based jetting. This might lead to direct cell-electrospinning 
with very high resolution in the future.
6. Cell-Instructive Matrix Design
The ECM provides a 3D microenvironment for cells of 
structural and functional proteins, proteoglycans, and gly-
coproteins.[182] Various tissues have unique compositions, 
conformations, and architectures in their normal state, as 
well as unique signatures when diseased.[183,184] Yet, there 
are numerous proteins (e.g., fibronectin, collagen, laminin, 
fibrinogen, vitronectin, thrombospondin, elastin, tenascin, and 
osteopontin) which are found in the ECM.[184–187] For example, 
laminin is abundant in the basement membrane of tissue, 
which possess a more sheet like structure, whereas interstitial 
matrices of tissues are chiefly made of fibrillar proteins like col-
lagens I, III, and fibronectin.[188,189]
ECM macromolecules provide structural support and mechan-
ical integrity of the local microenvironment, have attachment 
sites for cell surface receptors, and regulate growth factors.[193] 
It can act as a reservoir for latent signaling factors that can be 
released via degradation and can influence cell processes such 
as migration and proliferation.[182] Additionally, cells actively 
remodel their local microenvironment by exerting forces on the 
matrix, secreting new proteins, or degrading proteins through 
matrix metalloproteases (MMPs), which in turn leads to changes 
in the proliferation, migration and adhesion, and creates a com-
plex dynamic reciprocity between cells and the ECM.[194]
Given that cells respond sensitively to their microenviron-
ment, it becomes paramount to precisely control proteins used 
in vitro in order to mimic the target tissue as close as possible 
while keeping in mind how complex is complex enough, which 
is often undefined. Parameters to consider when designing an 
artificial matrix are protein composition, morphology, relative 
amount, fibril density, matrix compliance, and the orientation 
of the protein structures[195–197] (Table 4).
A common technique for creating an attachment surface 
for cells on synthetic material scaffolds involves physisorption 
of proteins. Thereby, the protein needs to undergo a change in 
conformation to adsorb on the surface. Solution conditions such 
as concentration, solvent, and substrate properties dominate the 
morphology characteristics of the adsorbed protein layer.[195–197] 
This stochastic adhesion may lead to denaturation or inacces-
sibility of binding sides.[196] In vivo, cells form protein matrices, 
especially fibrillar fibronectin under mechanical tension by 
stretching the protein leading to exposed self-association sites. 
To mimic this process in vitro, various approaches ranging 
from stirring, mechanically pulling over electrical forces, to the 
use of active denaturants, have been investigated.[198–201]
Another technique is the production of decellularized 
matrices via cell secretions. The disadvantage is time-consuming 
cell growth and multiple processing steps of decellularization 
before adding the cells of interest.[202] Even though the matrix 
closely mimics natural ECM, the chemical composition is unde-
fined and makes it difficult to control the ECM properties.
Another possibility is to use the fact that fibronectin fibrillo-
genesis occurs at the interface of protein solution,[203] air, 
and the scaffold. Forcing the interface through the micropo-
rous scaffold resulted in fibronectin fibrils in the interpillar 
space.[204] These engineered fibronectin networks are fibrillar in 
nature and stable in cell culture conditions. This process can 
also be extended to other proteins. The shear-driven hydrody-
namically deposited ECM forms remarkably stable fibrillar pro-
tein networks, which are similar to the protein matrix secreted 
by human mammary fibroblasts. Engineered ECMs will enable 
investigation into the bidirectional relationship between cells 
and their protein microenvironments.[89,204] Beside the use 
of natural proteins such as collagen or fibronectin, there are 
synthetic polymers available as well. Due to their durability 
and cell compatibility, hydrogels are used as a protein replace-
ment, or addition, to provide a supportive cell environment.[205] 
Through coordinated control, physical properties such as den-
sity and structure can be tuned to investigate cell behavior.[206] 
Hydrogel-based biomaterials can be spatially controlled by bio-
printing or photopatterning.[157,207]
Similarly, synthetic polymers and naturally derived proteins 
are being explored for their potential in 2PP. For instance, 
bovine serum albumin (BSA) is a common natural material 
used in 2PP, but it lacks relevance as a biomaterial for studying 
cell–ECM interactions. Ovsianikov et al. generated scaffolds 
composed of a methacrylate-modified gelatin (GelMod) for the 
expansion of adipose-derived stem cells (Figure 8A).[208] Su et al. 
reported on a series of 2PP printed structures composed of a 
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Table 4. Key elements of ECM design.
Key elements of ECM design
• Tunable architecture and topology
The ECM provides structural support and mechanical integrity as well 
as orientation to the cells.
• Tunable mechanical stiffness
The mechanical properties should fit to the target tissue to guide cell 
differentiation and integration of the artificial tissue into the surrounding 
environment inside the body.
• Tunable biochemical compositions
Each kind of tissue has his own composition of proteins and growth factors. 
By tuning the material composition, the resulting tissue can be influenced.
• Spatial control
Microfabrication techniques as 3D printing or photo-patterning provide 
special control of the biomaterials mimicking the ECM.
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mixture of laminin/BSA in the presence of Rose Bengal dye for 
studying stem cell migration (Figure 8B).[209] Collagen-I was also 
implemented in 2PP with high spatial resolution.[210] A critical 
outstanding question for all of these materials is whether they 
retain any of the biologically relevant protein configurations 
following the multiphoton crosslinking process. Subsequent 
studies should be focused on this aspect of their design.
7. Cellularization of Scaffolds
Once a material system has been developed for a given tissue 
engineering application, it can be categorized as an acellular 
or cellular scaffold. Cellularization of a scaffold can be done 
postproduction of the scaffold prior to implantation, during 
production prior to implantation or by the host in which it is 
implanted.
7.1. Acellular Scaffolds
Examples of acellular scaffolds include many of the previously 
synthetic or naturally derived 3D printed or traditionally manu-
factured porous scaffolds. Acellular scaffolds can further be 
derived from decellularized tissues that have been reviewed in 
more detail elsewhere.[211] Though not a micromanufacturing 
strategy, these represent both biochemically and structurally 
complex tissue scaffolds. Ott et al. successfully decellularized a 
rat heart and gave rise to perfusion-decellularization of whole 
organs.[212] Since then, companies like Miromatrix Medical 
Inc. have scaled this to larger, human-relevant sized organs.[213] 
However, given their nonautologous source, these scaffolds 
have the potential to elucidate unwanted immune responses, 
and they can also be challenging to handle in vitro in an aseptic 
manner. While some organs can be efficiently decellularized, 
reseeding those decellularized tissues with autologous cells 
of the proper type, and spatial arrangement remains a great 
challenge.
Generally, acellular scaffolds can be directly implanted into 
the host and rely solely on integration of cells from the wound 
site into the scaffold. Alternatively, they can be cellularized in 
vitro. If cellularized in vitro, this can be done by either static 
or dynamic processes. Any postproduction cell seeding inher-
ently requires a porous scaffold. A static seeding process would 
imply one in which a cell suspension is exposed to an acellular 
scaffold without mixing, where cells would settle into the scaf-
fold via gravitational force. If the scaffold is extremely porous 
this may be possible but likely will not lead to a homogeneous 
distribution of cells. A dynamic process may be necessitated by 
a desire for homogeneity of seeding or if the scaffold is not as 
porous. Given that most mammalian cells are ≈10–20 µm in 
diameter, porous features closer to size of cells may require 
additional force be imparted on the system to seed cells. This 
could be in the form of a fluidic flow (mixing) or by a light 
centrifugation.
Once cells are seeded in the tissue scaffold, a major chal-
lenge is to direct them to arrange and behave in a way that is 
advantageous for the intended application. Early on, this gave 
way to substantial efforts to pattern 3D surfaces with adhe-
sive ligands to orient cells spatially on microfibers, to utilize 
different peptide sequences to elicit variable cell binding, as 
well as to immobilize growth factors on surfaces to drive cell 
behavior.[82,214,215] Many of these instances have been exhaus-
tively outlined elsewhere.[77]
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Figure 8. Scaffolds fabricated using multiphoton polymerization of biomacromolecules. A) Gelatin scaffolds support the expansion of adipose-derived 
stem cells. Scale is 1 mm (left) 300 µm (middle) and 1 mm, 600 µm, and 300 µm from top to bottom (right). Adapted under the terms of the 
CC-BY Creative Commons Attribution license (https://creativecommons.org/licenses/by/3.0/).[208] Copyright 2011, The Authors. Published by MDPI. 
B) Laminin and BSA modules are used to support mesenchymal stem cell growth. Scale is 10 µm. Reproduced with permission.[209] Copyright 2012, 
American Chemical Society.
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7.2. Cellular Scaffolds
7.2.1. Bioprinting
Bulk encapsulation of cells into a hydrogel is a common strategy 
for both synthetic and natural scaffolds that may be too dense for 
a postproduction seeding strategy. Modern approaches allow for 
selective deposition of bioinks containing cells or cell aggregates 
in a process referred to as “bioprinting.”[144] This is typically 
achieved via droplet- or extrusion-based printing. In both cases, 
either the printhead or stage are controlled and translate over xy 
and z directions. Droplet printing requires that the polymer or 
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Figure 9. System for 3D printing of heterogenous polymers, hydrogels, and cell solutions. A) Schematic for the integrated tissue and organ printer 
(ITOP) unit and patterning architecture. B) System is applied for the reconstruction of a calvarial defect. A,B) Reproduced with permission.[221] Copy-
right 2016, Springer Nature.
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prepolymer solution have gelation kinetics that match the depo-
sition speed, which can limit the library of materials available 
for this technique. Extrusion-based printing passes polymer or 
prepolymer material through a nozzle in a continuous ejection 
method to maintain contact with the stage and is typically slower 
than droplet printing. In either case, the solutions may be sub-
ject to additional thermal, mechanical, or light treatment.
Cell-hydrogel printing of defined 3D structures can have 
advantages over classical seeding on acellular scaffolds, such as 
controlled cell placement, high seeding efficiencies, and control 
over cell–matrix properties. However, many limitations plague 
current systems, such as low printing resolutions, lengthy solu-
tion optimization procedures, and creating large 3D structures 
that do not collapse from their own weight. Several strategies 
for overcoming these limitations have been discussed, such as 
including sacrificial support structures, and rapid crosslinking 
to facilitate larger build volumes.[216] The underlying biofab-
rication techniques that enable these processes, as well as 
their advantages and disadvantages, have recently been revi
ewed.[37,143,144,217–219] Exciting emerging techniques focus on 
incorporating aspects of tissue heterogeneity that are found in 
native tissue, via deposition of multiple materials or compart-
ments sequentially or simultaneously. Layer-by-layer deposi-
tion of scaffold support materials and cell-laden bioinks was 
achieved using a multihead 3D printing system to print large-
scale proof-of-concept architectures resembling tooth, kidney, 
ear, and skin.[216,220] This system, known as the integrated 
composite tissues/organs building system (ICBS) and the inte-
grated tissue and organ printer (ITOP) system are two recent 
examples of integrated systems for printing heterogeneous 
solutions (Figure 9). ITOP demonstrated a proof-of-concept 
printing of an anatomical defect of large tissue structures by 
incorporating microchannels to facilitate nutrient diffusion and 
combining hydrogels and synthetic polymers for imparting 
mechanical strength.[221]
Printing of vascularized constructs is another area in which 
precise deposition of cells has enabled significant progress 
(Figure 10).[222] For example, vascularized perfusable scaffolds 
composed of multiple cell types were generated using 3D bio-
printing.[119,223] In this approach, vascular inks composed of 
Pluronic F-127 and thrombin were printed on a perfusion chip 
along with cell-laden ECM bioinks of gelatin and fibrinogen. 
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Figure 10. 3D printing of vasculature. A) Heterogeneous printing of three different inks (GelMA containing different cell types and a sacrificial Plu-
ronic F127 ink). Adapted with permission.[119] Copyright 2014, Wiley-VCH. B) Perfusable vasculature enables thick (1 cm) osteogenic tissues to grow. 
Adapted with permission.[223] Copyright 2016, The Authors. Published by National Academy of Sciences, USA. Scale is 1.5 mm (center) and 100 µm 
and 200 µm from top to bottom (right).
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Casting of gelatin, fibrinogen, cells, thrombin, and transglu-
taminase eventually induces polymerization into fibrin and 
crosslinking of the gelatin matrix.[223] After cooling, the vas-
cular inks liquefy and are evacuated to create a hollow vascular 
network, which is then seeded with endothelial cells and con-
nected to an external pump. Using this approach, 1 cm thick 
osteogenic tissues were supported in long-term culture and 
provide the potential for studying ex vivo cell interactions in 
the future.
8. Conclusion and Further Perspective
Information-assisted manufacturing of complex functional tis-
sues with various cell types is now achievable. When mimicking 
natural tissue, it is necessary to understand the cell’s native 
environment, especially cell–cell interactions as well as cell–
ECM interactions. The challenge is to implement vast amounts 
of available information about cells, tissue structure, and bio-
logical interactions into an artificial product without dramati-
cally increasing its complexity. High-throughput techniques 
based on experimental design and data analysis in material 
design and biological characterization will play an important 
role in building an intelligent architecture for imitating native 
tissue. Due to the emerging trend of using information-driven 
design and CAD-based micromanufacturing techniques, dif-
ferent structures and scaffold sizes can be produced. However, 
material choice, protein matrix design, and cellularization will 
always depend on the target organ fabrication of thick artifi-
cial tissue is limited due to passive transport of nutrients and 
metabolic waste. Further progress in integrating vascular tissue 
and combining different types of tissues will lead to enhanced 
architectures and biological functions.
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